
Orakl Oncology is a pioneering precision oncology company founded in 2023 as a spin-off from the Gustave Roussy Institute, focused on accelerating oncology drug development through a first-in-class…

Orakl Oncology is a pioneering precision oncology company founded in 2023 as a spin-off from the Gustave Roussy Institute, focused on accelerating oncology drug development through a first-in-class…
Founded: 2023
Headquarters: Villejuif, Île-de-France, France
Focus: AI-powered precision oncology platform for drug development
Flagship products: O-Predict; O-Validate
Notable funding: Seed round (Dec 2024); ~€11M–€15M total raised
28 employees
Cancer drug development, with an emphasis on colorectal and pancreatic cancers
2023
Biotechnology Research
≈€11,000,000
Seed round announced Dec 3, 2024; reporting cites nondilutive support from Bpifrance and total capital raised to date near €15M in some sources.
“Bpifrance; Singular; additional investors recorded (Amazon Web Services, HCVC, SistaFund, Speedinvest, Verve Ventures)”
Job description
At Orakl Oncology , we are accelerating the development of oncology treatments. Today, fewer than 5% of new cancer drugs succeed in clinical trials. Clearly, new methods are needed. We combine cutting-edge biology and AI to build the next generation of insight platforms with the world’s largest cohort of patient tumor avatars. These avatars fuel our AI-powered predictive engine , helping to anticipate clinical trial outcomes, validate therapies, and uncover new drug candidates.
Our mission is simple yet ambitious: to s who need them - and to make drug development smarter, faster, and more personalized. We collaborate with top hospitals, research institutes, and pharmaceutical companies worldwide. Backed by leading investors, we are a p at the intersection of science and technology.
Your next opportunity is in here somewhere. Sign up to explore 70,000+ startups and their open roles. No spam. No gamification. Just jobs.
70,000+
Startups
80,000+
Open Roles
3,900+
New This Week
| Company |
|---|
We are looking for a passionate and dynamic hands-on scienti st to build Orakl's CRISPR and functional genomics capabilities from the ground up. Reporting directly to the Principal Scientist, you'll design and run gene-perturbation and drug screens in our patient-derived tumor organoids, generating the high-quality biological data that powers our AI predictive engine.
Must have
Nice to have
Interested? Apply and we will be in touch!